| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2011: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Research Abstract |
This study aimed to establish a novel therapy for skin defect using allogeneic cultured skin substitute combined with wound dressing containing epidermal growth factor (EGF). Finally we developed an excellent two-layered cultured dermal substitute (CDS). The upper layer is a hyaluronic acid (HA) and collagen (Col) spongy sheet with epidermal growth factor (EGF). The lower layer is a HA spongy sheet and Col gel containing fibroblasts. The CDS is promising, because there is no risk of cellular damage caused by cryopreservation, thawing and rinsing processes. The CDS is prepared in serum-free medium, followed by placing on a wound surface. The critical issue is how to reduce the cellular damage during a prolonged period of incubation in serum-free medium. EGF-incorporating CDS can be used after a period of several days incubation in serum-free medium. This period is sufficient for transport of CDS from manufacturing facilities to hospitals. This CDS is promising for a practical therapy.
|
